Abshagen U, Spörl S, L'age M
Klin Wochenschr. 1978 Feb 1;56(3):135-8. doi: 10.1007/BF01478568.
In 5 healthy subjects and in 5 patients with decompensated liver diseases, the concentrations of cortisol, canrenone and canrenoate-K were determined after single doses and after a long-term treatment with spironolactone. The concentrations of the metabolites of spironolactone were determined fluorimetrically, those of cortisol by a highly specific radioimmunoassay with previous chromatographic separation. As a result, non-interaction between spironolactone medication and cortisol metabolism, even at high dose and long-term treatment conditions, was established neither in normal test subjects nor in patients with liver failure.
在5名健康受试者和5名失代偿性肝病患者中,测定了单次给药后以及螺内酯长期治疗后的皮质醇、坎利酮和坎利酸钾浓度。螺内酯代谢物的浓度采用荧光法测定,皮质醇浓度采用高度特异性放射免疫分析法并经先前的色谱分离后测定。结果表明,无论是在正常受试对象还是肝功能衰竭患者中,即使在高剂量和长期治疗条件下,螺内酯用药与皮质醇代谢之间均未发现相互作用。